Genital warts and cost of care in England

Sexually Transmitted Infections

Volumn 87, Issue 6, 2011, Pages 464-468

  Desai, Sarika ^a   Wetten, Sally ^a   Woodhall, Sarah C ^a   Peters, Lindsey ^a   Hughes, Gwenda ^a   Soldan, Kate ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CONDYLOMA ACUMINATUM; DISEASE REGISTRY; HEALTH CARE COST; HEALTH CENTER; HOSPITAL CARE; HOSPITAL COST; PREVALENCE; PRIORITY JOURNAL; REFERENCE DATABASE; UNITED KINGDOM;

ADULT; AMBULATORY CARE; CONDYLOMATA ACUMINATA; COST OF ILLNESS; ENGLAND; FAMILY PRACTICE; FEMALE; HEALTH CARE COSTS; HUMANS; INCIDENCE; LENGTH OF STAY; MALE; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; RECURRENCE; VENEREOLOGY; YOUNG ADULT;

EID: 80052957716     PISSN: 13684973     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/sti.2010.048421     Document Type: Article

References (28)

1. Health Protection Agency. STI Annual Data Tables. 2009. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb-C/1203348026613 (accessed 25 Aug 2010).
2. British Association for Sexual Health and HIV. United Kingdom National Guideline on the Management of Ano-genital Warts. 2007. http://www.bashh.org/ documents/86/86.pdf (accessed 24 Aug 2010).
3. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010;28:6247-55.
4. The FUTURE II Group. Effect of prophylactic human papillomavirus L1 virus-like particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-8.
5. Dillner J, Kjaer SK, Wheeler CM, et al; The FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493.
6. Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009;85:499-502.
7. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet 2011;11:39-44.
8. Jit M, Choi YH, Edmunds J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008;337:a769.
9. Department of Health. Introduction of the human papillomavirus vaccine into the national immunisation programme: announcement of vaccine to be used. http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/ Dearcolleagueletters/DH-085582 (accessed 20 Sep 2010).
10. Department of Health. Annual HPV vaccine coverage in England: 2009/2010. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-123795 (accessed 10 Feb 2011).
11. Walley T, Mantgani A. The UK general practice research database. Lancet 1997;350:1097-9. (Pubitemid 27437871)
12. Woodhall SC, Jit M, Soldan K, et al. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect 2011;87:458-63.
13. Curtis L. General practitioner - unit costs. In: Curtis L, ed. Unit costs of Health and Social Care 2009. Canterbury: University of Kent, 2009:123.
14. The Information Centre. 2006/07 UK General Practice Workload Survey. http://www.ic.nhs.uk/webfiles/publications/gp/GP%20Workload%20Report.pdf (accessed 9 Aug 2010).
15. The Information Centre. The Casemix Service. HRG4 2008/09 Reference Costs Grouper. http://www.ic.nhs.uk/services/the-casemix-service/using-this-service/ reference/archived-past-groupers-and-documentation/reference-cost/ hrg4-2008-09-reference-costs-grouper (accessed 27 Jun 2011).
16. The Department of Health. NHS Reference Costs 2008-09. Appendix NSRC1: NHS trust reference cost schedules. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-111591 (accessed 21 Jun 2010).
17. Yung M, Denholm R, Peake J, et al. Distribution and characteristics of sexual health service provision in primary and community care in England. Int J STD AIDS 2010;21:650-2.
18. Nouraei SA, O'Hanlon S, Butler CR, et al. A multidisciplinary audit of clinical coding accuracy in otolaryngology: financial, managerial and clinical governance considerations under payment-by-results. Clin Otolaryngol 2009;34:43-51.
19. Cassell J, Mercer CH, Sutcliffe L, et al. Trends in sexually transmitted infections in general practice 1990-2000: population based study using data from the UK general practice research database. BMJ 2006;332:332-4. (Pubitemid 43253747)
20. Castellsagué X, Cohet C, Puig-Tintoré LM, et al. Epidemiology and cost of treatment of genital warts in Spain. Eur J Public Health 2009;19:106-10.
21. Hillemanns P, Breugelmans JG, Gieseking F, et al. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis 2008;8:76.
22. Lukasiewicz E, Aractingi S, Flahault A. Incidence and management of condylomata acuminata by French general physicians. Ann Dermatol Venereol 2002;129:991-6. (Pubitemid 35230579)
23. Pirotta M, Stein AN, Conway EL, et al. Genital warts incidence and health care resource utilisation in Australia. Sex Transm Infect 2010;86:181-6.
24. Marra F, Ogilvie G, Colley L, et al. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect 2009;85:111-15.
25. Hoy T, Singhal PK, Willey VJ, et al. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin 2009;25:2343-51.
26. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003;36:1397-403. (Pubitemid 36702873)
27. Monsonégo J, Breugelmans JG, Bouée S, et al. Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France. Gynécol Obstet Fertil 2007;35:107-13.
28. Pearce V, Grant A, Adams E. Technical Document - Phase 1 Methodology of the Proposed Integrated Sexual Health Pricing and Currencies for London. Community Sexual Health Services. London: Pathway analytics, 2009.